1-2 of 2
Jacob Zhang
Close
Sort by
Journal Articles

Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from the Tourmaline-MM1 Study

Ajeeta B Dash, PhD, Jacob Zhang, PhD, Lei Shen, PhD, Bin Li, PhD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Hervé Avet-Loiseau, MDPhD, Nizar Bahlis, MD, Philippe Moreau, Paul Richardson, Alessandra Di Bacco, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 473.
https://doi.org/10.1182/blood-2018-99-114614
Published: 2018
Journal Articles

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

Alessandra Di Bacco, PhD, Nizar J. Bahlis, MD, Nikhil C Munshi, MD, Hervé Avet-Loiseau, MD PhD, Tamás Masszi, MD, Luísa Viterbo, MD, Ludek Pour, MD PhD, Peter Ganly, BMBCh, PhD, Michele Cavo, MD, Christian Langer, MD, Shaji Kumar, MD, S. Vincent Rajkumar, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Bin Li, Sunita Badola, Lei Shen, Jacob Zhang, Ling Wang, PhD, Dixie-Lee Esseltine, MD, Katarina Luptakova, Helgi van de Velde, MD PhD, Paul G. Richardson, MD, Philippe Moreau
Journal: Blood
Blood (2016) 128 (22): 243.
https://doi.org/10.1182/blood.V128.22.243.243
Published: 2016